[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital of Patras\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":274},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,52,84,118,160,183,210,232,254],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100639403","ultrasound-guided-distal-radial-artery-vs-conventional-transradial-access-for-interventional-coronary-angiography-100639403",false,"NCT07617259","UltraSound Guided Distal Radial Artery vS Conventional Transradial Access for Interventional Coronary Angiography","US-DRASTIC","Inclusion Criteria:\n\n* Indication for Invasive coronary angiography\n\nExclusion Criteria:\n\n* STEMI\n* Renal replacement therapy patients\n* Serious dermal or bone deformity of the radiocarpal joint\n* Shock","ALL","18 Years",{"count":19,"type":20},1400,"ESTIMATED","INTERVENTIONAL",[23],"NA","Comparative study of ultrasound-guided distal radial access versus conventional radial access regarding the incidence of vascular access crossover.",[26,27],"Radial Artery Access","Distal Radial Artery Access (dTRA)",[29,30,31,32,33,34,35,36,37,38],"distal radial artery","dra","coronary","ultrasound","distal","dtra","u\u002Fs","ultrasound guided","ICA","coronary angiography","RECRUITING","2026-05-24",{"date":42,"type":43},"2026-06-01","ACTUAL",{"date":45,"type":43},"2026-05-12",{"date":47,"type":20},"2028-11-01",{"name":49,"class":50},"University Hospital of Patras","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100637073","carotid-endatorectomy-and-general-anesthesia-assessment-and-evaluation-of-cerebral-ischemic-damage-with-clinical-laboratory-and-imaging-parameters-100637073","NCT07602400","CAROTID ENDATORECTOMY AND GENERAL ANESTHESIA: Assessment and Evaluation of Cerebral Ischemic Damage With Clinical, Laboratory and Imaging Parameters","CAROTID ENDATORECTOMY AND GENERAL ANESTHESIA: Assessment and Evaluation of Cerebral Ischemic Damage With Clinical, Laboratory and Imaging Parameters: a Single-center, Prospective, Randomized, Comparative Clinical Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* ASA 1-4\n* For planned carotid endarterectomy\n* Absence of major established neurological deficits that would not allow neurological evaluation and performance of the MoCA test\n* Patient consent to participate in the study\n\nExclusion Criteria:\n\n* Age ≤ 18 years\n* Presence of major neurological deficits that will not allow neurological evaluation and performance of the MoCA test\n* Claustrophobia and inability to enter the MRI scanner\n* Cochlear implants\n* Intracranial vascular clips\n* Neurostimulation systems\n* Pacemaker incompatible for MRI\n* Small cell and non-small cell lung cancer\n* Neuroendocrine tumors\n* Melanoma\n* Seminoma\n* Teratoma\n* Malignant pheochromocytoma\n* CNS or NM diseases\n* Schizophrenia\n* Allergy or contraindication to any anesthetic factor\n* Patient refusal to participate in the study",{"count":60,"type":20},160,"3 Days","OBSERVATIONAL","This study is aiming to provide us with information about the neuroprotective effect of two commonly used anesthetic drugs, during carotid endarterectomy. A day before sugery, a brain MRI will be performed as well as a cognitive function assessment test. The day of the surgery each patient will receive anesthesia either by using intravenous anesthetic drug or an inhalation agent and during the intraoperative period, the Anesthesiologist will draw a small amount of blood in three different times in order to measure brain biomarkers. A day after the surgery, a second brain MRI will be performed as well as a second cognitive function assessment test and their results will be compared to the preoperative ones. The study will focus on whether there is a higher incidence of microischemic brain lesions shown in imaging tests or whether cognitive function is impaired postoperative or whether brain biomarkers indicating brain damage are elevayed with any of these drugs and thus conclude which one shows or not a neuroprotective effect, with the condition that no change in the regular anesthesia management was made and no danger was imposed on the patient.",[65,66,67],"Carotid Artery Stenosis","Endarterectomy, Carotid","Ischemic Cerebrovascular Accident",[69,70,71,72,73,74],"carotid endarterectomy","MRI brain","general anesthesia","neuroprotection","propofol","sevoflurane","NOT_YET_RECRUITING","2026-05-18",{"date":78,"type":43},"2026-05-22",{"date":80,"type":20},"2026-05-30",{"date":82,"type":20},"2027-12",{"name":49,"class":50},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":101,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":51},"100612203","left-bundle-branch-pacing-vs-right-ventricular-pacing-on-ahre-burden-in-patients-with-preserved-lvef-100612203","NCT07250529","Left Bundle Branch Pacing vs Right Ventricular Pacing on AHRE Burden in Patients With Preserved LVEF","Comparison of Left Bundle Branch Pacing Versus Conventional Right Ventricular Pacing on AHRE Burden in Patients With Preserved Left Ventricular Ejection Fraction and High Ventricular Pacing Dependency (LBBP-AHRE Trial): A Randomized Study","LBBP-AHRE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Scheduled implantation of a dual-chamber pacemaker for:\n\nPermanent complete heart block Permanent second-degree AV block (Mobitz II or Mobitz I)\n\n* Documented preserved LVEF (≥50%)\n* Sinus rhythm at baseline\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* History of paroxysmal, persistent, or permanent atrial fibrillation\n* Previous atrial fibrillation ablation (catheter-based or surgical)\n* LVEF \\\u003C 50%\n* Sinus node disease\n* Transient AV block requiring pacemaker implantation\n* Significant structural or valvular heart disease\n* Requirement for pacemaker system upgrade during the study period\n* Requirement for antiarrhythmic therapy for causes other than atrial fibrillation\n* Existing pacemaker or other cardiac device requiring modification for study participation\n* Enrollment in another clinical trial that could interfere with study endpoints or pacing parameters\n* Contraindication to LBBP or associated lead implantation procedure\n* Life expectancy \\\u003C 12 months\n* Any condition judged by the investigator to compromise participation or the integrity of study data",{"count":93,"type":20},244,[23],"This prospective, randomized controlled trial aims to evaluate the effect of left bundle branch pacing (LBBP) compared with conventional right ventricular (RV) pacing on the cumulative duration (total time) of atrial high-rate episodes (AHREs) in patients with preserved left ventricular ejection fraction (LVEF) who are expected to require frequent ventricular pacing.\n\nAtrial High-Rate Episodes (AHREs) are defined as episodes of atrial tachyarrhythmia that are automatically recorded by device diagnostics and detected by implanted cardiac devices. These episodes usually have an atrial rate ≥170 beats per minute and a duration ≥6 minutes. AHREs are linked to a higher risk of thromboembolic events and clinical atrial fibrillation (AF), and they may indicate subclinical AF or other atrial tachyarrhythmias.\n\nChronic RV pacing has been linked to mechanical and electrical dyssynchrony, which may encourage atrial remodeling and the development of AF. LBBP provides a more physiological ventricular activation and may reduce atrial tachyarrhythmia time (AHRE time).\n\nPatients with LVEF \\>50% and atrioventricular (AV) conduction disorders requiring a dual-chamber pacemaker will be randomized to either conventional RV septal pacing or LBBP.",[97,98,99,100],"Atrial Fibrillation (AF)","Pacemaker Therapy","Atrioventricular Block","Preserved Ejection Fraction",[102,103,104,105,106,107,108,109],"Left bundle branch pacing","Cardiac electrophysiology","Right ventricular pacing","AHRE burden","Preserved ejection fraction","Heart Failure","Quality of life","Pacing-induced cardiomyopathy (PICM)","2026-03-10",{"date":112,"type":43},"2026-03-13",{"date":114,"type":43},"2026-02-05",{"date":116,"type":20},"2029-06-20",{"name":49,"class":50},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":128,"studyType":62,"phases":4,"briefSummary":129,"conditions":130,"keywords":135,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":51},"100616406","study-of-ahre-burden-in-patients-undergoing-bachmann-bundle-area-pacing-and-left-bundle-branch-pacing-100616406","NCT07305194","Study of AHRE Burden in Patients Undergoing Bachmann Bundle Area Pacing and Left Bundle Branch Pacing.","Study of Atrial High-Rate Episode Burden in Patients Undergoing Concurrent Bachmann Bundle Area Pacing and Left Bundle Branch Pacing , Compared With Either Left Bundle Branch Pacing or Conventional Right Ventricular Pacing.","AHRE-BLAST","Inclusion Criteria:\n\n* Adult patients (≥ 18 years) with a clear indication for permanent pacing, according to ESC guidelines \\[15\\] for the management of conduction disturbances (e.g. symptomatic bradycardia, complete atrioventricular block, sinus node dysfunction).\n* Sinus rhythm at the time of implantation, with no documented episodes of atrial fibrillation prior to implantation, either in the medical history or in previous recordings (ECG, Holter, telemetry).\n* Ability to be followed up for at least 24 months after implantation.\n* Provision of written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* History of atrial fibrillation prior to implantation, either permanent or paroxysmal, documented on ECG, Holter, or telemetry.\n* Prior pharmacological or interventional treatment for AF (e.g. antiarrhythmic drugs, catheter ablation).\n* Inability to comply with long-term follow-up or non-adherence to follow-up visits.\n* Contraindications to pacemaker lead placement at the selected sites.\n* Participation in another study that could influence the results.\n* Previous device implantation.",{"count":127,"type":20},460,"24 Months","This prospective observational study evaluates the burden of Atrial High-Rate Episodes (AHRE) in patients without a prior history of atrial fibrillation who undergo concurrent Bachmann Bundle Area Pacing (BBAP) and Left Bundle Branch Pacing (LBBP). Physiological pacing at these sites aims to improve interatrial conduction and reduce the risk of atrial arrhythmias.\n\nThe study includes a comparative assessment across three patient groups:\n\n1. BBAP + LBBP (physiological pacing group)\n2. Right Atrial Appendage (RAA) pacing + LBBP\n3. Conventional pacing - RAA and Right Ventricular (RV) pacing AHRE burden will be quantified via device diagnostics and remote monitoring at 3, 12 and 24 months post-implantation. Episodes will be classified by duration (0-6 min, 6-24 h, \\>24 h), differentiating subclinical AHRE from clinically documented AF.\n\nSecondary analyses include electrocardiographic changes (P-wave indices), the need for antiarrhythmic therapy, and comprehensive echocardiographic evaluation of atrial function (e.g., LA strain, conduction delays, LAVI).\n\nThe study aims to determine whether physiological pacing (BBAP + LBBP) provides superior protection against AHRE development compared with RAA + LBBP and conventional pacing strategies.",[131,97,132,133,134],"Atrial Arrhythmia","Pacemaker Implantation","Left Bundle Branch Pacing","Conduction System Pacing",[136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151],"Atrial High-Rate Episodes (AHRE)","Subclinical Atrial Fibrillation","Bachmann Bundle Area Pacing (BBAP)","Left Bundle Branch Pacing (LBBP)","Physiological Pacing","Interatrial Conduction","Atrial Synchrony","P-wave Duration","Atrial Electromechanical Remodeling","Atrial Strain","Left Atrial Reservoir Strain","Inter-atrial Conduction Delay (IACD)","Speckle Tracking Echocardiography","Left Atrial Volume Index (LAVI)","Atrial Arrhythmias","Device-Detected AF","2025-12-11",{"date":154,"type":43},"2025-12-26",{"date":156,"type":20},"2026-01-01",{"date":158,"type":20},"2028-04-14",{"name":49,"class":50},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":21,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":51},"100569043","correlation-of-typical-lbbb-mechanical-activation-pattern-by-2d-strain-echocardiography-with-acute-gwe-improvement-in-patients-receiving-lbbp-or-conventional-bivp-for-cardiac-resynchronization-therapy-echo-lbbp-100569043","NCT06689111","Correlation of Typical LBBB Mechanical Activation Pattern by 2D Strain Echocardiography With Acute GWE Improvement in Patients Receiving LBBp or Conventional BiVp for Cardiac Resynchronization Therapy (Echo LBBp)","Investigation of Whether the Presence of the Typical LBBB- Mechanical Stimulation Pattern - Documented Through 2DSE (Two-dimensional Strain Echocardiography) - is Associated With Increased Rates of Acute Improvement in Global Myocardial Work Efficiency (GWE) Compared to the Absence of This Activation Pattern, in Patients in Need of Device Implantation for Cardiac Resynchronization Therapy in Whom LBBp is Chosen Compared to the Classic Biventricular Pacing Method","ECHO-LBBp","Inclusion Criteria:\n\n* \\>18 years \\\u003C 90 years\n* Patients with a documented indication for resynchronization therapy \\[symptomatic patients despite optimal medication, HFrEF (EF\\\u003C35%), LBBB QRS morphology\\]\n* COMPLETE LBBB (LBBB defined as QRS\\>130msec, wide \"notched or slurred\" R wave in leads I, aVL, V5, V6 and occasional RS pattern in V5, V6, absence of Q waves in leads I, V5 and V6 but in lead aVL narrow Q wave may be present in the absence of myocardial pathology, R peak time \\>60ms in leads V5 and V6 but normal in leads V1, V2, V3 when small R's are discernible in precardial leads, ST and T usually opposite to QRS direction)\n* Patients with ntraventricular septum diameter \\>8 mm\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients with RBBB or atypical LBBB QRS morphology\n* Patients eligible for an upgrade procedure (already carring a PM or ICD)\n* Patients with hypertrophic cardiomyopathy","90 Years",{"count":170,"type":20},100,[23],"The present study is a multicenter interventional non randomised study in patients requiring an implantable device for cardiac resynchronization therapy. Its primary objective is to investigate whether the presence of a specific echocardiographic contraction pattern before implantation is associated with increased rates of acute improvement in myocardial function (as measured by an ultrasound) and to compare the improvement in two groups of patients based on the type of pacing (biventricular or left-sided pacing)",[174],"Heart Failure With Reduced Ejection Fraction (HFrEF)","2025-11-29",{"date":177,"type":43},"2025-12-05",{"date":179,"type":43},"2024-05-23",{"date":181,"type":20},"2026-11-30",{"name":49,"class":50},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":191,"targetDuration":193,"studyType":62,"phases":4,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":51},"100588504","vascular-access-registry-100588504","NCT06942260","Vascular Access Registry","Vascular Access Registry (VARegistry) - Prospective Registry of Vascular Access","VARegistry","Inclusion Criteria:\n\n* Indication for percutaneous cardiac procedure\n\nExclusion Criteria:\n\n* No exclusion criteria exist",{"count":192,"type":20},1157,"30 Days","The Vascular Access Registry (VARegistry) is a prospective patient registry that will be conducted at the Hemodynamic Laboratory of the Cardiology Clinic of the University General Hospital of Patras.\n\nThe puncture of the vessel will be performed either using palpation, anatomical landmarks or using ultrasound guidance, depending on the ability and preference of each operator. Patients who meet all admission criteria and no exclusion criteria will be admitted to the study.\n\nPatients \\>18 years of age presented with indication for any percutaneous cardiac procedure will be included in the study. No exclusion criteria exist.\n\nThe vascular puncture will be performed according to current guidelines and on the basis of recent scientific data. If the attempt to obtain access from the selected location is unsuccessful, the access location will be changed. The choice of the new access location in case of failure of the originally selected one is subject to the preference of each operator.\n\nParticipants will be monitored for the period they remain hospitalized, depending on the initial indication of intervention, and a follow-up with a vascular ultrasound after one month is recommended.\n\nThe primary endpoint is the percentage of success of the puncture at the initial access point.\n\nThe secondary endpoints are as follows:\n\n* Percentages of successful puncture of vascular access with and without the use of ultrasound guidance\n* Occlusion rate of the access artery before discharge\n* Crossover rate of access site during procedure\n* Time to sheath placement during procedure\n* Total intervention time\n* Procedure duration (from the sheath insertion to the completeness of the procedure)\n* Total fluoroscopy time\n* Total DAP (Dose area product)\n* Air Kerma\n* Time required for hemostasis\n* Vascular complications \\*\n* Classification of hematomas (modified classification by EASY)\\*\\*\n* Vascular implication of access artery using ultrasound monitoring of patients at 30 days\n\n  * VARC criteria \\*\\* if the forearm has been used",[196,197],"Vascular Access","Coronary Interventions",[196,197,199,200,201],"Coronary Angiography","Radial Artery","Distal Radial Artery","2025-04-16",{"date":204,"type":43},"2025-04-24",{"date":206,"type":43},"2025-01-01",{"date":208,"type":20},"2026-06-30",{"name":49,"class":50},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":21,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":4},"100558588","deep-versus-moderate-neuromuscular-blockade-in-bariatric-surgery-100558588","NCT06553066","Deep Versus Moderate Neuromuscular Blockade in Bariatric Surgery","Deep Versus Moderate Neuromuscular Blockade in Bariatric Surgery:","Inclusion Criteria:\n\n* Patients aged ≥18 years ASA II-III who are to undergo planned laparoscopic bariatric surgery\n\nExclusion Criteria:\n\n* ASA 4 patients\n* Maternal population\n* Patients who are not scheduled to receive general anesthesia, but some other type of anesthesia.\n* Contraindicated patients: administration of neuromuscular blockade, suppression of spontaneous respiration, and those with an indication for awake intubation or surgical airway.\n* Patients with neuromuscular diseases\n* Patients who refuse to participate in the study.","65 Years",{"count":219,"type":20},50,[23],"The aim of this study is to investigate the effect of depth of neuromuscular blockade on the surgical field, patient postoperative pain, intestinal motility, the incidence of postoperative nausea and vomiting and the effect of deep versus moderate neuromuscular blockade on postoperative atelectasis quantitatively using chest computed tomography.This is a prospective, randomized, controlled clinical-controlled study in patients ≥18 years old scheduled to undergo elective bariatric surgery.",[223],"Neuromuscular Blockade","2024-08-10",{"date":226,"type":43},"2024-08-14",{"date":228,"type":20},"2024-08",{"date":230,"type":20},"2026-08",{"name":49,"class":50},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":239,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":21,"phases":242,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":51},"100552551","comparison-of-lma-protector-with-endotracheal-tube-evaluation-of-respiratory-mechanical-parameters-during-controlled-ventilation--possibility-of-pulmonary-aspiration-100552551","NCT06474559","Comparison of Lma-Protector With Endotracheal Tube: Evaluation of Respiratory Mechanical Parameters During Controlled Ventilation & Possibility of Pulmonary Aspiration","Comparison of Protector Laryngeal Mask With Endotracheal Tube: Evaluation of Respiratory Mechanical Parameters During Controlled Ventilation & Possibility of Pulmonary Aspiration","Inclusion Criteria:\n\n* Patients aged ≥18 years ASA1-2 who are to undergo planned urological surgery of low or intermediate severity, under general anesthesia in the lithotomy position.\n\nExclusion Criteria:\n\n* patients \\\u003C 18 years old.\n* Patients who are going to undergo an emergency\u002Furgent operation\u002F trauma patients.\n* Maternal population.\n* Patients who are not scheduled to receive general anesthesia, but some other type of anesthesia.\n* Patients in whom LMA placement is contraindicated, such as patients at high risk for reflux and aspiration of gastric contents (eg, history of gastroesophageal reflux, hiatal hernia, pyloric stenosis, gastrointestinal obstruction, morbid obesity).\n* Patients who meet at least one of the four RODS difficulty criteria.\n* Contraindicated patients: administration of neuromuscular blockade, suppression of spontaneous respiration, and those with an indication for awake intubation or surgical airway.\n* Patients who refuse to participate in the study.",true,{"count":241,"type":20},80,[23],"The aim of this prospective, randomized, comparative, controlled clinical study is to compare laryngeal mask airway ProtectorTM with the endotracheal tube, regarding to the respiratory mechanical parameters during controlled mechanical ventilation and the prevalence of aspiration. Aspiration will be evaluated by detecting and quantifying pepsin (a marker of gastric aspiration) and α-amylase (a marker of salivary aspiration) in the bronchoalveolar lavage ( mini BAL) of patients ≥18 years old, ASA 1-2, undergoing selective low-risk surgery under general anesthesia in a lithotomy position.",[245],"Mechanical Ventilation","2024-06-19",{"date":248,"type":43},"2024-06-25",{"date":250,"type":20},"2024-06",{"date":252,"type":20},"2025-03",{"name":49,"class":50},{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":261,"targetDuration":262,"studyType":62,"phases":4,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":51},"100535838","the-amara-as-much-as-reasonably-achievable-study-100535838","NCT06257030","The AMARA (As Much As Reasonably Achievable) Study","The AMARA (As Much As Reasonably Achievable) Study: Radioembolization of Large Inoperable Liver Tumors","Inclusion Criteria:\n\n* Age \\>18 yr\n* Both sexes eligible for study\n* Patients with primary or secondary liver tumors\n* Liver dominant disease\n* At least one lesion greater than 5.0 cm in maximum diameter\n* Life-expectancy \\> 3 months\n* FLR \\>40% or greater than 500mls\n* Must be able to tolerate pre-treatment CT scan , DSA and 99mTc-MAA infusion and imaging with SPECT\u002FCT scan\n* Able to schedule and tolerate post-treatment Y90 PET\u002FCT imaging\n* Able to tolerate follow-up imaging with dynamic contrast CT liver phase or MRI with liver specific contrast at 3mo, 6mo, 9mo, 1yr, 2.0 yr, and 3.0 years.\n\nExclusion Criteria:\n\n* Child Pugh \\> B\n* Bilirubin \\>2 mg\u002Fdl\n* Albumin\\\u003C3.0\n* Central portal invasion\n* Multi-focal bilobar disease\n* Disseminated extrahepatic disease\n* Lung shunt \\>20% or a estimated Lung dose \\> 20 Gy\n* Focuses of extra-hepatic liver uptake.\n* Patients that cannot tolerate addition follow-up imaging.",{"count":170,"type":20},"2 Years","Subjects with large inoperable liver tumors defined as at least 1 lesion larger than 5cm in maximum diameter. For the purposes of the present study, we define the AMARA principle in intensified regional TARE as a planned irradiated tumor dose \\>200Gy by the partition model. The purpose of the study is to evaluate the safety and efficacy of Y90 high dose radioembolization for the management of large inoperable liver tumors. In addition, to correlate the safety and efficacy with the post-treatment dosimetry analysis (by MIM Software Inc) based on 90Y-PET\u002FCT imaging.",[265],"Liver Cancer","2024-04-21",{"date":268,"type":43},"2024-04-24",{"date":270,"type":43},"2024-02-05",{"date":272,"type":20},"2027-02-05",{"name":49,"class":50},""]